DaVita (DVA) closed at $227.99 on Aug 4, 2026, down 2.4% on the day. The stock is down 3.3% over the past month, up 48.0% over three months, up 100.7% year to date and up 64.6% over the past year. It trades 7.9% below its 52-week high of $247.49 and 125.7% above its 52-week low of $101.00. The close sits above its 50-day moving average ($218.19) and above its 200-day moving average ($157.69).
DVA is scheduled to report earnings on Oct 23, 2026, after market close.
DVA options were pricing 48% at-the-money implied volatility on Oct 7, 2026, an IV rank of 61 over the past year.
DaVita is scheduled to report on Oct 23, 2026, after market close.
Yes — the Aug 4, 2026 close of $227.99 is 44.6% above the 200-day average of $157.69.
DVA closed 7.9% below its 52-week high of $247.49.
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
